How should azathioprine be initiated in a patient with ulcerative colitis who is in remission, including baseline laboratory testing (complete blood count with differential, liver enzymes, renal function, thiopurine methyltransferase [TPMT] and nudix hydrolase 15 [NUDT15] activity), dosing strategy (start‑low, go‑slow), and monitoring schedule?

How to Start Azathioprine for Ulcerative Colitis

Azathioprine should be reserved for maintenance of remission in ulcerative colitis patients who are already in remission, not for active disease induction, and requires pre-treatment TPMT/NUDT15 genetic testing with dose adjustments based on results. 1

Clinical Context and Role

The AGA guidelines explicitly recommend against using thiopurine monotherapy for induction of remission in active moderate-to-severe ulcerative colitis (conditional recommendation, very low certainty) 1. However, thiopurines are suggested for maintenance of remission once achieved (conditional recommendation, low certainty) 1. This reflects their slow onset of action—clinical trials typically assessed outcomes at 26 weeks or beyond 2.

In contemporary practice, azathioprine is most appropriately used either:

• As maintenance monotherapy in patients already in remission
• In combination with TNF antagonists, vedolizumab, or ustekinumab (which shows superior efficacy to either agent alone) 2, 1

Pre-Treatment Testing (Mandatory)

Genetic Testing

Before initiating azathioprine, obtain TPMT and NUDT15 genotyping or phenotyping 3, 4. This is critical because:

• TPMT deficiency: Present in ~6-9% of patients with intermediate activity and ~1% with absent activity 5, 6
• NUDT15 variants: Particularly prevalent in Asian populations (R139C variant), strongly associated with myelotoxicity 7, 8
• Patients with variants in both genes require even more aggressive dose reductions 4

Baseline Laboratory Testing

Obtain the following before starting therapy 3:

• Complete blood count with differential and platelets
• Liver function tests (AST, ALT, bilirubin, alkaline phosphatase)
• Renal function (creatinine, BUN)

Dosing Strategy

Standard Dosing (Normal TPMT/NUDT15 Activity)

Start with 50 mg daily (approximately 0.6-1.2 mg/kg/day) rather than weight-based dosing from the outset 6. This "start-low, go-slow" approach is safer than the traditional 2.5 mg/kg/day target used in clinical trials 9.

• Japanese studies demonstrate that 50 mg/day is effective for maintaining remission (88% remission rate at 6 months) with lower toxicity 6
• Only 6% of patients on low-dose therapy (30 mg 6-MP or 50 mg azathioprine daily) developed bone marrow suppression versus 44% on standard doses 6
• Most community gastroenterologists take longer than the 2-week escalation recommended in trials, which may actually be prudent 9

Dose escalation: If tolerated after 4-8 weeks, can gradually increase toward 1.5-2.5 mg/kg/day based on clinical response and laboratory monitoring.

Dose Adjustments for Genetic Variants

TPMT intermediate activity (heterozygous): Start at 25-50% of standard dose 4

TPMT deficient (homozygous variant): Consider alternative therapy; if azathioprine used, start at 10% of standard dose with extreme caution 4

NUDT15 heterozygous (particularly R139C): Start at 25 mg daily and increase very cautiously. These patients have a 5.4-fold increased risk of myelotoxicity when escalating from 25 mg to 50 mg daily 7. Final maintenance doses are typically lower (0.83 mg/kg/day vs 1.04 mg/kg/day in wild-type) without compromising efficacy 7.

NUDT15 homozygous variant: Consider alternative therapy 4

Both TPMT and NUDT15 variants: Strongly consider alternative therapy; if used, requires substantial dose reduction and intensive monitoring 4

Critical Drug Interactions

Allopurinol or Febuxostat (Xanthine Oxidase Inhibitors)

Reduce azathioprine dose to 25-33% of usual dose when co-administered with allopurinol 3. Concomitant use with febuxostat is not recommended 3. XO inhibition blocks a major inactivation pathway, causing dangerous accumulation of active metabolites.

Aminosalicylates

Use caution when combining with sulfasalazine, mesalamine, or olsalazine as these inhibit TPMT enzyme in vitro 3. While commonly co-prescribed, monitor more closely for myelotoxicity.

Ribavirin

Avoid this combination—ribavirin inhibits IMDH, leading to accumulation of the toxic metabolite 6-MTITP, causing severe pancytopenia 3.

Monitoring Schedule

Complete Blood Count Monitoring

This is non-negotiable and cannot be replaced by genetic testing 3:

• Weekly during the first month
• Twice monthly during months 2-3
• Monthly thereafter, or more frequently with dose changes

Additional Monitoring

• Liver enzymes: Check at same intervals as CBC initially, then every 3 months
• Renal function: Every 3 months
• Consider metabolite monitoring (6-TGN and 6-MMP levels) if available, though not routinely required 9

Common Pitfalls and Safety Considerations

Gastrointestinal Hypersensitivity

A distinct syndrome of severe nausea, vomiting, diarrhea, fever, and myalgias can occur within the first several weeks 3. This is reversible upon discontinuation and will recur within hours of rechallenge 3. This is not dose-related and represents true drug intolerance.

Myelosuppression Risk

Even with normal TPMT/NUDT15, myelosuppression can occur 5. The 2006 prospective study found that TPMT testing did not prevent all cases of myelotoxicity—3 of 4 patients who developed bone marrow suppression had high TPMT levels 5. This underscores why CBC monitoring cannot be replaced by genetic testing.

Malignancy Risk

Long-term use increases lymphoma risk, particularly when combined with TNF antagonists (HR 2.53 for combination vs TNF monotherapy; HR 2.35 vs thiopurine monotherapy) 2. Discuss this risk explicitly with patients, especially younger individuals who may be on therapy for decades.

Infection Risk

Patients must be counseled to report signs of infection immediately. Combination with other immunosuppressants (ACE inhibitors, co-trimoxazole) increases leukopenia risk 3.

When NOT to Use Azathioprine

• Active moderate-to-severe disease requiring induction: Use biologics or tofacitinib instead 1
• Recent blood transfusion: TPMT phenotyping will be inaccurate 3
• Concurrent febuxostat use: Not recommended 3
• Concurrent ribavirin: Contraindicated 3
• Pregnancy: Teratogenic potential requires careful risk-benefit discussion 3
• Nursing mothers: Not recommended due to transfer in breast milk and tumorigenicity concerns 3

Practical Algorithm

1. Confirm patient is in remission (not active disease)
2. Obtain TPMT and NUDT15 genetic testing
3. Obtain baseline CBC, LFTs, renal function
4. Review medication list for allopurinol, febuxostat, ribavirin, aminosalicylates
5. Start 50 mg daily (or 25 mg if NUDT15 heterozygous, or dose-reduce for TPMT variants per above)
6. Monitor CBC weekly × 4 weeks, then twice monthly × 2 months, then monthly
7. Assess tolerance at 4-8 weeks; if tolerated and genetic testing normal, can gradually escalate
8. Counsel patient on infection risk, need for monitoring, GI hypersensitivity symptoms, and malignancy risk

This approach balances efficacy with safety, recognizing that azathioprine remains a cost-effective maintenance option in resource-limited settings 2 but requires meticulous monitoring and patient selection.